SELLAS Life Sciences (SLS) Stock Surges Over 200% After Phase 3 Leukemia Vaccine Win
Key Takeaways
- •SELLAS Life Sciences stock surged more than 200% on Tuesday, touching a reported peak gain of 240%, after the positive Phase 3 REGAL results were released.
- •The galinpepimut-S vaccine met the REGAL trial's primary overall survival endpoint, reducing the risk of death by 41% (hazard ratio 0.59, two-sided p-value 0.035) compared with the best available therapy.
- •Median survival reached 24.0 months with GPS versus 14.7 months in the control group, in a study population of patients in second or later remission who had no stem cell transplant option.
- •SELLAS plans to meet with the FDA about a faster filing route and is preparing a Biologics License Application targeted for the first half of 2027.
- •The company ended September with $134.7 million in cash while its second leukemia program, the Phase 2 CDK9 inhibitor SLS009, progresses with early findings expected before year-end.

SELLAS Life Sciences Group, Inc. (SLS) saw its stock surge more than 200% on Tuesday after the company reported positive results from its pivotal Phase 3 trial of an experimental leukemia vaccine. One early report (Investing.com) put the gain at 240% at its peak, and buyers showed little hesitation in moving into the shares.
The rally came in direct response to the positive Phase 3 REGAL results, in which the company's cancer vaccine cut the risk of death by 41% in patients with acute myeloid leukemia (AML), an aggressive cancer of the blood and bone marrow.
What the REGAL Trial Showed
The trial tested galinpepimut-S, known as GPS, in patients with acute myeloid leukemia and met its primary goal of overall survival, the endpoint widely regarded as the most direct measure of a cancer treatment's benefit.
$SLS +300% (Market cap: ~$6B) Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint. Its vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in… pic.twitter.com/ApAngqbE9U
— Wall St Engine (@wallstengine) November 17, 2026
Patients who received GPS had a 41% lower risk of death than those on the best available treatment. The hazard ratio was 0.59, and the two-sided p-value was 0.035.
Median survival reached 24.0 months among patients treated with GPS, compared with 14.7 months in the control group.
The analysis was carried out after 80 events had occurred, as the trial protocol required, with that timing specified in advance — a standard trial-design practice that removes discretion over when results are evaluated.
Every patient in the study had achieved a second or later complete remission and could not undergo a stem cell transplant, or was not eligible for one. GPS was administered on its own as maintenance therapy. That population is among the hardest to treat in AML, since a transplant is generally the main curative option once the disease has returned.
The vaccine's safety profile was consistent with earlier experience, and no new safety signals were observed. Most side effects were mild to moderate, with reactions at the injection site the most common.
What Comes Next for SELLAS
SELLAS plans to meet with the U.S. Food and Drug Administration to discuss a faster filing pathway and is preparing a Biologics License Application — the submission through which a sponsor seeks U.S. licensure of a biologic — targeted for the first half of 2027. More detailed data from the trial is expected at an upcoming medical conference, although the company has not been tied to a specific date in the reports. Until then, that FDA discussion and the detailed data presentation are the near-term markers of how the regulatory path takes shape.
The company's second leukemia program is also advancing. Tambiciclib, known as SLS009, is a CDK9 inhibitor in Phase 2 testing, and forty patients have enrolled in its study of newly diagnosed AML. Early findings are expected before year-end, and additional SLS009 data is slated for the American Society of Hematology meeting in December, the field's largest annual gathering for blood-disorder research.
Earlier work with SLS009 in relapsed or resistant AML showed response rates of 54% in monocytic AML and 57% in patients with TP53 mutations.
On the financial side, SELLAS ended September with $134.7 million in cash and equivalents. Its third-quarter net loss was $10.1 million, up from $6.8 million a year earlier.
Maxim analyst Jason McCarthy rates the stock a Buy with a $30 price target. He models GPS revenue starting in 2027 and SLS009 revenue in first-line AML in 2029. Tuesday's rally has pushed the stock much closer to that target.
This article originally appeared on Blockonomi.